|
1
|
Aggarwal BB, Bhardwaj A, Aggarwal RS,
Seeram NP, Shishodia S and Takada Y: Role of resveratrol in
prevention and therapy of cancer: Preclinical and clinical studies.
Anticancer Res. 24:2783–2840. 2004.PubMed/NCBI
|
|
2
|
Brown VA, Patel KR, Viskaduraki M, Crowell
JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli
G, et al: Repeat dose study of the cancer chemopreventive agent
resveratrol in healthy volunteers: Safety, pharmacokinetics, and
effect on the insulin-like growth factor axis. Cancer Res.
70:9003–9011. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel KR, Scott E, Brown VA, Gescher AJ,
Steward WP and Brown K: Clinical trials of resveratrol. Ann NY Acad
Sci. 1215:161–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr
and Walle UK: High absorption but very low bioavailability of oral
resveratrol in humans. Drug Metabol Dispos. 32:1377–1382. 2004.
View Article : Google Scholar
|
|
5
|
Vitrac X, Desmoulière A, Brouillaud B,
Krisa S, Deffieux G, Barthe N, Rosenbaum J and Mérillon JM:
Distribution of [14C]-trans-resveratrol, a cancer chemopreventive
polyphenol, in mouse tissues after oral administration. Life Sci.
72:2219–2233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wenzel E, Soldo T, Erbersdobler H and
Somoza V: Bioactivity and metabolism of trans-resveratrol orally
administered to Wistar rats. Mol Nutr Food Res. 49:482–494. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Crozier A, Jaganath IB and Clifford MN:
Dietary phenolics: Chemistry, bioavailability and effects on
health. Nat Prod Rep. 26:1001–1043. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Duynhoven J, Vaughan EE, Jacobs DM,
Kemperman RA, van Velzen EJ, Gross G, Roger LC, Possemiers S,
Smilde AK, Doré J, et al: Metabolic fate of polyphenols in the
human superorganism. Proc Natl Acad Sci USA. 108 Suppl 1:pp.
4531–4538. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rotches-Ribalta M, Andres-Lacueva C,
Estruch R, Escribano E and Urpi-Sarda M: Pharmacokinetics of
resveratrol metabolic profile in healthy humans after moderate
consumption of red wine and grape extract tablets. Pharmacol Res.
66:375–382. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Radko Y, Christensen KB and Christensen
LP: Semi-preparative isolation of
dihydroresveratrol-3-O-β-d-glucuronide and four resveratrol
conjugates from human urine after oral intake of a
resveratrol-containing dietary supplement. J Chromatogr B Analyt
Technol Biomed Life Sci. 930:54–61. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bode LM, Bunzel D, Huch M, Cho GS, Ruhland
D, Bunzel M, Bub A, Franz CM and Kulling SE: In vivo and in vitro
metabolism of trans-resveratrol by human gut microbiota. Am J Clin
Nutr. 97:295–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jung CM, Heinze TM, Schnackenberg LK,
Mullis LB, Elkins SA, Elkins CA, Steele RS and Sutherland JB:
Interaction of dietary resveratrol with animal-associated bacteria.
FEMS Microbiol Lett. 297:266–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Azorín-Ortuño M, Yáñez-Gascón MJ, Vallejo
F, Pallarés FJ, Larrosa M, Lucas R, Morales JC, Tomás-Barberán FA,
García-Conesa MT and Espín JC: Metabolites and tissue distribution
of resveratrol in the pig. Mol Nutr Food Res. 55:1154–1168. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu LF, Desai SD, Li TK, Mao Y, Sun M and
Sim SP: Mechanism of action of campothecin. Ann N Y Acad Sci.
922:1–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuo LJ and Yang LX: Gamma-H2AX-a novel
biomarker for DNA double-strand breaks. In Vivo. 22:305–309.
2008.PubMed/NCBI
|
|
16
|
Gavrieli Y, Sherman Y and Ben-Sasson SA:
Identification of programmed cell death in situ via specific
labeling of nuclear DNA fragmentation. J Cell Biol. 119:493–501.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shiloh Y: ATM and related protein kinases:
Safeguarding genome integrity. Nat Rev Cancer. 3:155–168. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fernandez-Capetillo O, Lee A, Nussenzweig
M and Nussenzweig A: H2AX: The histone guardian of the genome. DNA
Repair (Amst). 3:959–967. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Srivastava N, Gochhait S, de Boer P and
Bamezai RN: Role of H2AX in DNA damage response and human cancers.
Mutat Res. 682:180–188. 2009. View Article : Google Scholar
|
|
21
|
Redon C, Pilch D, Rogakou E, Sedelnikova
O, Newrock K and Bonner W: Histone H2A variants H2AX and H2AZ. Curr
Opin Genet Dev. 12:162–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shroff R, Arbel-Eden A, Pilch D, Ira G,
Bonner WM, Petrini JH, Haber JE and Lichten M: Distribution and
dynamics of chromatin modification induced by a defined DNA
double-strand break. Curr Biol. 14:1703–1711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bom D, Curran DP, Kruszewski S, Zimmer SG,
Strode J Thompson, Kohlhagen G, Du W, Chavan AJ, Fraley KA,
Bingcang AL, et al: The novel silatecan
7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high
lipophilicity, improved human blood stability, and potent
anticancer activity. J Med Chem. 43:3970–3980. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Van Hattum AH, Pinedo HM, Schlüper HM,
Hausheer FH and Boven E: New highly lipophilic camptothecin BNP1350
is an effective drug in experimental human cancer. Int J Cancer.
88:260–266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Colin D, Limagne E, Jeanningros S, Jacquel
A, Lizard G, Athias A, Gambert P, Hichami A, Latruffe N, Solary E
and Delmas D: Endocytosis of resveratrol via lipid rafts and
activation of downstream signaling pathways in cancer cells. Cancer
Prev Res (Phila). 4:1095–1106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li G, He S, Chang L, Lu H, Zhang H, Zhang
H and Chiu J: GADD45α and Annexin A1 are involved in the apoptosis
of HL-60 induced by resveratrol. Phytomedicine. 18:704–709. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kartal M, Saydam G, Sahin F and Baran Y:
Resveratrol triggers apoptosis through ceramide metabolizing genes
in human K562 chronic myeloid leukemia cells. Nutr Cancer.
63:637–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gupta SC, Kannappan R, Reuter S, Kim JH
and Aggarwal BB: Chemosensitization of tumors by resveratrol. Ann N
Y Acad Sci. 1215:150–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Banerjee S, Bueso-Ramos C and Aggarwal BB:
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary
carcinogenesis in rats by resveratrol: Role of nuclear
factor-kappaB, cyclooxygenase 2, and matrix metalloproteinase 9.
Cancer Res. 62:4945–4954. 2002.PubMed/NCBI
|
|
30
|
Li ZG, Hong T, Shimada Y, Komoto I, Kawabe
A, Ding Y, Kaganoi J, Hashimoto Y and Imamura M: Suppression of
N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis
in F344 rats by resveratrol. Carcinogenesis. 23:1531–1536. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee EO, Lee HJ, Hwang HS, Ahn KS, Chae C,
Kang KS, Lu J and Kim SH: Potent inhibition of Lewis lung cancer
growth by heyneanol A from the roots of Vitis amurensis through
apoptotic and anti-angiogenic activities. Carcinogenesis.
27:2059–2069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu HS, Pan CE, Yang W and Liu XM:
Antitumor and immunomodulatory activity of resveratrol on
experimentally implanted tumor of H22 in Balb/c mice. World J
Gastroenterol. 9:1474–1476. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tessitore L, Davit A, Sarotto I and
Caderni G: Resveratrol depresses the growth of colorectal aberrant
crypt foci by affecting bax and p21(CIP) expression.
Carcinogenesis. 21:1619–1622. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baur JA and Sinclair DA: Therapeutic
potential of resveratrol: The in vivo evidence. Nat Rev Drug
Discov. 5:493–506. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kimura Y and Okuda H: Resveratrol isolated
from Polygonum cuspidatum root prevents tumor growth and metastasis
to lung and tumor-induced neovascularization in lewis lung
carcinoma-bearing mice. J Nutr. 131:1844–1849. 2001.PubMed/NCBI
|
|
36
|
Busquets S, Ametller E, Fuster G, Olivan
M, Raab V, Argilés JM and López-Soriano FJ: Resveratrol, a natural
diphenol, reduces metastatic growth in an experimental cancer
model. Cancer Lett. 245:144–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weng YL, Liao HF, Li AF, Chang JC and
Chiou RY: Oral administration of resveratrol in suppression of
pulmonary metastasis of BALB/c mice challenged with CT26 colorectal
adenocarcinoma cells. Mol Nutr Food Res. 54:259–267. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cadenas S and Barja G: Resveratrol,
melatonin, vitamin E, and PBN protect against renal oxidative DNA
damage induced by the kidney carcinogen KBrO3. Free Radic Biol Med.
26:1531–1537. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Quincozes-Santos A, Andreazza AC, Nardin
P, Funchal C, Gonçalves CA and Gottfried C: Resveratrol attenuates
oxidative-induced DNA damage in C6 glioma cells. Neurotoxicology.
28:886–891. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burkhardt S, Reiter RJ, Tan DX, Hardeland
R, Cabrera J and Karbownik M: DNA oxidatively damaged by
chromium(III) and H(2)O(2) is protected by the antioxidants
melatonin, N(1)-acetyl-N(2)-formyl-5-methoxykynuramine, resveratrol
and uric acid. Int J Biochem Cell Biol. 33:775–783. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu GA and Zheng RL: Protection against
damaged DNA in the single cell by polyphenols. Pharmazie.
57:852–854. 2002.PubMed/NCBI
|
|
42
|
Russell GK, Gupta RC and Vadhanam MV:
Effect of phytochemical intervention on dibenzo[a,l]pyrene-induced
DNA adduct formation. Mutat Res. 774:25–32. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Singh K, Bhori M and Marar T: α-Tocopherol
mediated amelioration of camptothecin-induced free radical damage
to avert cardiotoxicities. Hum Exp Toxicol. 34:380–389. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Singh KC, Kaur R and Marar T: Ameliorative
effect of vitamin E on chemotherapy induced side effects in rat
liver. J Pharmacol Toxicol. 6:481–492. 2011. View Article : Google Scholar
|
|
45
|
Singh KC and Marar T: Acute toxicity of
camptothecin and influence of α-tocopherol on hematological and
biochemical parameters. J Cell Tiss Res. 11:2833–2837. 2011.
|
|
46
|
Guo Y, Shi M, Shen X, Yang C, Yang L and
Zhang J: Capecitabine plus irinotecan versus 5-FU/leucovorin plus
irinotecan in the treatment of colorectal cancer: A meta-analysis.
Clin Colorectal Cancer. 13:110–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vanhoefer U, Harstrick A, Achterrath W,
Cao S, Seeber S and Rustum YM: Irinotecan in the treatment of
colorectal cancer: Clinical overview. J Clin Oncol. 19:1501–1518.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fujita K, Kubota Y, Ishida H and Sasaki Y:
Irinotecan, a key chemotherapeutic drug for metastatic colorectal
cancer. World J Gastroenterol. 21:12234–12248. 2015. View Article : Google Scholar : PubMed/NCBI
|
